A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2017 Planned End Date changed from 3 Mar 2018 to 3 Aug 2018.
- 25 Aug 2017 Planned primary completion date changed from 3 Aug 2017 to 3 Aug 2018.
- 09 Mar 2017 Planned primary completion date changed from 3 Mar 2017 to 3 Aug 2017.